The abstract is read at the publisher; the summary is JClub's.
In a prospective cohort of adults with pulmonary MDR/RR-TB in Kazakhstan with favorable end-of-treatment outcomes, only 1 recurrence occurred after shortened all-oral regimens (0.2%, 95% CI 0.0–1.0%).
- Why it matters: Recurrence after treatment is a key measure of regimen durability, and programmatic evidence is needed for shortened all-oral options in people without prior second-line drug exposure.
- What they did: Adults received one of three all-oral, five-drug regimens and were followed microbiologically and clinically for up to 12 months after treatment, totaling 578 favorable end-of-treatment outcomes.
- The result: The very low observed recurrence rate (1 case; 0.2%, 95% CI 0.0–1.0%) suggests these regimens have excellent durability in this programmatic setting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.